Acute coronary syndrome and myocardial infarction
107 results
1 - 100Acute coronary syndrome and myocardial infarction
Diagnostic coronary angiography
Coronary heart disease
Pain severity does not predict outcomes with AMI
For treatment of acute coronary syndrome, prasugrel is better than ticagrelor at preventing recurrent MIs at 1 year
High-sensitivity troponin I of less than 5 ng/L has negative predictive value of 99.9% for cardiac death at 1 year
Bivalirudin = abciximab + heparin for non-STEMI
Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome Stable (no update expected for reasons given in 'What's new')
Antithrombotic agents in primary health care
Statins for acute coronary syndrome
Routine or selective invasive strategy for acute coronary syndrome
Adding ezetimibe to moderate-dose statin reduces nonfatal MI only (NNT = 58 for 6 years)
Patients with non-ST-elevation acute coronary syndromes do not need immediate intervention
Mortality rate in patients with recent ACS and endoscopy is similar to that in patients with ACS and no endoscopy
Signs and symptoms not helpful in diagnosis of AMI/ACS
Escitalopram reduces risk of adverse cardiac events in adults with depression and acute coronary syndrome
Dyspepsia
Early CT angiography for suspected acute coronary syndrome reduces further ischemic testing; no effect on long-term clinical outcomes
Apixaban increases bleeding with no benefit in high-risk patients with ACS
Coronary CT angiogram allows for safe discharge of low-risk patients with chest pain
Statins for acute coronary syndrome Stable (no update expected for reasons given in 'What's new')
Hyperbaric oxygen therapy for acute coronary syndrome Stable (no update expected for reasons given in 'What's new')
Similar outcomes after PCI in hospitals with or without on-site cardiac surgery (CPORT-E)
Exercise stress test
Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes: Cochrane systematic review
Accelerated protocol identifies chest pain patients at low risk for major cardiac events
In ACS, 5 yrs of invasive tx decreases MI but not all cause mortality (FRISC-II)
Additional testing of limited benefit in patients with new-onset chest pain
Two-hour protocol identifies patients at low risk of ACS
Adding CCTA to chest pain assessment reduces likelihood of nonfatal MI (SCOT-HEART)
Intensive lipid lowering reduces mortality following ACS
Clopidogrel monotherapy more effective than aspirin to prevent coronary events after PCI with drug-eluting stents (HOST-EXAM)
High-sensitivity troponin safely reduces admissions and duration of stay in the emergency department
Platelet-function testing doesn't improve outcomes in elderly patients with stents after ACS
Single nondetectable high-sensitivity troponin result rules out AMI
Flu vaccine reduces risk of adverse CV events in high-risk patients
ACC/AHA guidelines on dual antiplatelet therapy
Dabigatran associated with increased risk of coronary events
Pioglitazone does not increase cardiovascular events (PROactive)
Low-dose rivaroxaban improves outcomes in patients with ACS (ATLAS)
Warfarin therapy
Genotype-guided selection of oral P2Y12 inhibitor therapy no better than standard therapy after PCI for ACS or stable CAD
FDA: Clopidogrel/aspirin does not decrease overall mortality
Low HS-troponin I accurate in identifying patients at low risk of cardiac events
PSK9 inhibitor alirocumab reduces nonfatal MI in patients after acute coronary syndrome, but at high cost (ODYSSEY OUTCOMES)
Acute abdomen in the adult
CCTA reduces need for hospitalization in low to moderate risk patients in ED
Percutaneous transluminal coronary angioplasty with stents versus coronary artery bypass grafting for people with stable angina or acute coronary syndromes: Cochrane systematic review
Improved outcomes with early invasive strategy for ACS? Maybe, maybe not.
Better medication adherence with intervention; clinical outcomes unchanged
Ticagrelor (Brilinta) is no better than aspirin—and may be worse—for adults after CABG
Drug treatment for hypertension
Dyspnoea
Acute heart failure and pulmonary oedema
Intensive BP control modestly decreased the likelihood of a broad composite of CV events, but with methodologic limitations
For atrial fibrillation with ACS or PCI, apixaban plus clopidogrel (without aspirin) is preferred (AUGUSTUS)
Omega‐3 fatty acids for the primary and secondary prevention of cardiovascular disease New search for studies and content updated (conclusions changed)
Early invasive therapy better for non-ST ACS
6-month clopidogrel better than 24 after stent placement (PRODIGY)
ED chest pain protocol is safe and efficient
Treatment of dyslipidaemias
B vitamins, fish oil do not prevent CV events
Interpretation of adult ECG
In patients with vascular disease, treating sleep apnea does not reduce the risk of cardiovascular events
Similar number of cardiovascular events and reduced bleeding with abbreviated dual antiplatelet therapy after PCI
Little if any benefit to early invasive strategy for stable angina and at least moderate reversible ischemia (ISCHEMIA trial)
Niacin not effective in CAD with low HDL cholesterol (AIM-HIGH)
SBP of 120 instead of 140 in nondiabetic, high-risk elderly leads to significant benefits and some harms (SPRINT)
Lipid lowering is beneficial for secondary prevention but not primary prevention in patients 75 years and older
Increased readmissions and adverse events with intensification of antihypertensive regimen on hospital discharge
Transfusion thresholds for guiding red blood cell transfusion Edited (no change to conclusions)
Syncope: causes and investigations
SBP of 120 instead of 140 in adults 75 years or older = significant benefits and some harms (SPRINT)